BRCA2 and breast carcinoma: The cumulative 10-year risk of developing contralateral breast cancer in this cohort was 25%, 95% CI (23.5–26.4%) and 18.8%, 95% CI (17.1–20.5%) for BRCA1 and BRCA2 heterozygotes, respectively (Fig. S3).